What is the 13F Pro Quality Score for TMCI?

13F Pro ranks TREACE MEDICAL CONCEPTS, INC. (TMCI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TMCI's current score at https://13fpro.ai/research/TMCI (free sign-up required for the full ranking).

Which hedge funds own the most TMCI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TMCI include ARMISTICE CAPITAL,, GAGNON SECURITIES, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TMCI as soon as new 13F filings post.

Where does 13F Pro source TMCI data?

All TREACE MEDICAL CONCEPTS, INC. fundamentals and ownership data come directly from SEC EDGAR. TREACE MEDICAL CONCEPTS, INC. files with the SEC under CIK 1630627. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TMCI in?

TREACE MEDICAL CONCEPTS, INC. (TMCI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TMCI research updated on 13F Pro?

TMCI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TREACE MEDICAL CONCEPTS, INC.(TMCI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1630627 TMCI stock profile & AI dashboard →

13F Pro Quality Score

27.2/100

Rank #2,476 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

54.1/100

Profitability

13.5/100

Balance Sheet

6.2/100

Earnings Quality

30.0/100

Free Cash Flow

21.0/100

Institutional Flow

78.5/100

Revenue Scale

24.2/100

Dilution Risk

11.7/100

TMCI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TREACE MEDICAL CONCEPTS, INC. (TMCI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TMCI at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,476 of 2,879 stocks — the bottom half of the AI-ranked universe. TMCI scores in the top quartile across institutional flow (78.5). Areas of concern include balance sheet strength (6.2) and profitability (13.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TREACE MEDICAL CONCEPTS, INC. reports quarterly revenue of $47.2M, net income of $-18.0M, free cash flow of $4.2M. Top institutional holders of TMCI by reported 13-F value include ARMISTICE CAPITAL,, GAGNON SECURITIES, BlackRock,, based on the most recent SEC filings. TMCI trades on the Nasdaq exchange and files with the SEC under CIK 1630627. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TMCI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TREACE MEDICAL CONCEPTS, INC. directly from SEC EDGAR. TREACE MEDICAL CONCEPTS, INC.'s 13F Pro composite quality score has ranged between 22 and 37 since 2022, currently 27.2 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

Revenue

Q1 2026

$47.2M

Net Income

Q1 2026

$-18.0M

Free Cash Flow

Q1 2026

$4.2M

D/E Ratio

Q1 2026

0.75

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.6% YoY

$212.7MFY 2025

FY22 $141.8MFY23 $187.1MFY24 $209.4MFY25 $212.7M

Net Income

-5.8% YoY

$-59.0MFY 2025

FY22 $-42.8MFY23 $-50.0MFY24 $-55.7MFY25 $-59.0M

Operating Income

+2.8% YoY

$-54.2MFY 2025

FY22 $-34.8MFY23 $-51.4MFY24 $-55.7MFY25 $-54.2M

EPS (Diluted)

-3.3% YoY

$-0.93FY 2025

FY22 $-0.77FY23 $-0.81FY24 $-0.90FY25 $-0.93

Total Assets

-12.2% YoY

$190.6MFY 2025

FY22 $159.0MFY23 $251.9MFY24 $217.1MFY25 $190.6M

Total Debt

+7.5% YoY

$57.3MFY 2025

FY22 $52.7MFY23 $53.0MFY24 $53.3MFY25 $57.3M

Op. Cash Flow

+57.0% YoY

$-16.0MFY 2025

FY22 $-30.6MFY23 $-34.6MFY24 $-37.2MFY25 $-16.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$212.7M +1.6%	$209.4M +11.9%	$187.1M +31.9%	$141.8M +50.2%	$94.4M +64.6%	$57.4M
Net Income	$-59.0M -5.8%	$-55.7M -11.5%	$-50.0M -16.8%	$-42.8M -108.3%	$-20.6M -460.3%	$-3.7M
Operating Income	$-54.2M +2.8%	$-55.7M -8.3%	$-51.4M -47.6%	$-34.8M -111.0%	$-16.5M -2031.0%	$855.0K
EPS (Diluted)	$-0.93 -3.3%	$-0.90 -11.1%	$-0.81 -5.2%	$-0.77 -79.1%	$-0.43 -379.4%	$-0.09
Total Assets	$190.6M -12.2%	$217.1M -13.8%	$251.9M +58.4%	$159.0M +12.9%	$140.8M +236.8%	$41.8M
Total Debt	$57.3M +7.5%	$53.3M +0.6%	$53.0M +0.6%	$52.7M +79.5%	$29.4M -10.4%	$32.8M
Operating Cash Flow	$-16.0M +57.0%	$-37.2M -7.5%	$-34.6M -12.8%	$-30.6M -78.3%	$-17.2M -282.6%	$-4.5M

AI Insight: TMCI Ratio Trends

TMCI remains deeply unprofitable with Q1 2026 operating margin deteriorating to -36.4% and ROE collapsing to -93.1%, erasing Q4 2025's partial improvement.

• Operating margin swung from -0.3% in Q4 2024 to -36.4% in Q1 2026, confirming Q4 2024 was an anomaly, not a turnaround.

• ROIC deteriorated from -16.4% in Q4 2025 to -50.9% in Q1 2026, the worst reading in the dataset.

• D/E ratio has risen steadily from 0.47 in Q2 2024 to 0.75 in Q1 2026, signaling increasing leverage pressure.

⚠ Q4 2025 showed meaningful sequential improvement (OpMargin -9.5%, ROIC -16.4%) — monitor whether Q2 2026 replicates or extends that pattern.

⚠ D/E at 0.75 is the highest on record; continued leverage increase could constrain operational flexibility.

⚠ ROE hit -93.1% in Q1 2026, the most negative in the dataset, suggesting rapidly eroding equity base.

Get alerted when TMCI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TREACE MEDICAL CONCEPTS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TMCI

ARMISTICE CAPITAL, LLC
$8.5M6,364,000 sh
GAGNON SECURITIES LLC
$7.0M5,201,886 sh
BlackRock, Inc.
$4.5M3,340,023 sh
BANK OF AMERICA CORP /DE/
$4.3M3,214,293 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.0M1,461,507 sh
STATE STREET CORP
$1.7M1,235,518 sh
CIBC Bancorp USA Inc.
$1.6M1,218,353 sh
MILLENNIUM MANAGEMENT LLC
$1.5M1,148,115 sh
AQR CAPITAL MANAGEMENT LLC
$1.4M1,061,840 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4M1,010,843 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$8.5M	6,364,000
GAGNON SECURITIES LLC	$7.0M	5,201,886
BlackRock, Inc.	$4.5M	3,340,023
BANK OF AMERICA CORP /DE/	$4.3M	3,214,293
VANGUARD CAPITAL MANAGEMENT LLC	$2.0M	1,461,507
STATE STREET CORP	$1.7M	1,235,518
CIBC Bancorp USA Inc.	$1.6M	1,218,353
MILLENNIUM MANAGEMENT LLC	$1.5M	1,148,115
AQR CAPITAL MANAGEMENT LLC	$1.4M	1,061,840
GEODE CAPITAL MANAGEMENT, LLC	$1.4M	1,010,843

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TMCI on your watchlist

Track score changes the day TREACE MEDICAL CONCEPTS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TMCI a good stock to buy?

13F Pro's AI-powered analysis of TREACE MEDICAL CONCEPTS, INC. (TMCI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TMCI are available on the TMCI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TMCI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TMCI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TREACE MEDICAL CONCEPTS, INC.'s investment landscape.